Skip to content
Search

Latest Stories

NHS expands Covid vaccination to include vulnerable 5-11 year olds

The NHS on Sunday (January 30) expanded its Covid vaccination programme to include vulnerable children aged five to 11 years.

Eligible children include those with diabetes, immunosuppression, learning disabilities, and other conditions as outlined by the UK Health Security Agency in the Green Book.


Besides, children living with someone immunosuppressed will be eligible to get the first dose of the Covid vaccine in line with advice issued by the Joint Committee on Vaccination and Immunization (JCVI).

According to the NHS there are around 500,000 eligible children in the latest cohort.

GP and deputy lead for NHS vaccination programme Dr Nikki Kanani, said: “We know vaccines give significant protection against severe illness from Covid – including the omicron variant, so it is important that our youngest and most at-risk get protected.

“The NHS is now vaccinating the most at risk 5-11 year olds ensuring they get their vital dose of protection.

“Thousands of young people are still getting protected every day with millions vaccinated so far and we are asking parents not to delay coming forward – as soon as the NHS contacts you, please come forward so the NHS can protect their youngest against the virus”.

All eligible children will be offered two 10 microgram doses of the Pfizer vaccine eight weeks apart.

The NHS has already delivered over 3.5 million vaccinations to people aged 12-17, including over 2.4 million first doses.

It has asked parents and guardians to attend with their children and read the patient information in advance which includes details about the Covid-19 vaccination.

So far, the NHS has delivered over 115 million coronavirus vaccinations, including 43.9 million first doses and over 31 million booster doses.

More For You

Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less